WO2013129457A1 - 核酸の検出方法 - Google Patents

核酸の検出方法 Download PDF

Info

Publication number
WO2013129457A1
WO2013129457A1 PCT/JP2013/055085 JP2013055085W WO2013129457A1 WO 2013129457 A1 WO2013129457 A1 WO 2013129457A1 JP 2013055085 W JP2013055085 W JP 2013055085W WO 2013129457 A1 WO2013129457 A1 WO 2013129457A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
target nucleic
detection
capture probe
probe
Prior art date
Application number
PCT/JP2013/055085
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
洋二 上田
中村　史夫
Original Assignee
東レ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東レ株式会社 filed Critical 東レ株式会社
Priority to CN201380011166.7A priority Critical patent/CN104136611B/zh
Priority to EP13755881.3A priority patent/EP2843047B1/de
Priority to CA2865541A priority patent/CA2865541C/en
Priority to KR1020147025486A priority patent/KR102018934B1/ko
Priority to JP2013510382A priority patent/JP6206181B2/ja
Priority to US14/381,366 priority patent/US20150045249A1/en
Publication of WO2013129457A1 publication Critical patent/WO2013129457A1/ja

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Definitions

  • the present invention relates to a method for detecting a nucleic acid.
  • nucleic acids various nucleic acids / nucleic acid complementarity such as Northern blotting or Southern blotting can be used to examine the relationship between various genes and their biological function expression.
  • proteins the function and expression of proteins can be examined using protein / protein reactions, as typified by Western blotting.
  • a sandwich hybridization method is known as one of nucleic acid detection methods.
  • the sandwich hybridization method uses a capture probe immobilized on a filter.
  • the capture probe is complementary to the first portion of the target nucleic acid.
  • the capture probe bound to the filter is exposed to a sample to be examined for the target nucleic acid sequence and further exposed to a labeled detection probe that is complementary to the second portion of the target nucleic acid,
  • the second part is separate from the target part to which the first probe is complementary (that is, does not overlap with them) (Patent Documents 1 and 2, Non-Patent Document 1).
  • This approach eliminates the effort required to immobilize the sample on the filter, and the first probe can be selected to fit the support.
  • a sample is generally detected after amplification using a nucleic acid amplification technique such as a PCR method in advance. Detection sensitivity is enhanced by amplifying the target nucleic acid, but on the other hand, contaminated foreign DNA is also amplified, which raises concerns about false positives. In addition, when multiple genes are detected simultaneously, Primer sets were required according to the number of samples, and much effort was required for quality control.
  • An object of the present invention is to provide a nucleic acid detection method capable of detecting a target nucleic acid with high sensitivity even when the target nucleic acid is detected by sandwich hybridization without using nucleic acid amplification or sensitization techniques. That is.
  • the inventors of the present application have made it possible to simultaneously hybridize a plurality of detection probes that hybridize with different regions of the target nucleic acid in sandwich hybridization, without using nucleic acid amplification or sensitization techniques.
  • the present invention was completed by finding that the target nucleic acid can be detected with high sensitivity.
  • the present invention provides the following. (1) A target nucleic acid or fragmented product thereof, a plurality of detection probes, and a capture probe immobilized on a support are contacted sequentially or simultaneously, and the capture probe and the target nucleic acid or fragmented product thereof are contacted. And the target nucleic acid or fragmented product thereof is hybridized with the plurality of detection probes, whereby the plurality of detection probes are converted into the capture probe and the target nucleic acid or fragmented product thereof. Bonding to the support via, Detecting the plurality of detection probes bound to a support.
  • the step of sequentially or simultaneously contacting the target nucleic acid or fragmented product thereof, a plurality of detection probes, and a capture probe immobilized on a support comprises a plurality of the target nucleic acid or fragmented product thereof.
  • (3) The method according to (1) or (2), wherein the mode value of the nucleic acid length of the target nucleic acid to be hybridized with the capture probe or a fragmented product thereof is in the range of 100 bases to 1500 bases.
  • a plurality of detection probes are hybridized such that the distance from the capture probe binding position in the target nucleic acid to be hybridized with the capture probe or a fragmented product thereof is within the range of 1500 bases (1) to (3 ) Any one of the methods. (5) The distance from the capture probe binding position in the target nucleic acid to be hybridized with the capture probe or the fragmented product thereof is within the range of the mode value of the nucleic acid length of the target nucleic acid or the fragmented product or less. The method according to any one of (1) to (3), wherein a plurality of detection probes are hybridized.
  • the target nucleic acid fragmentation product obtained by fragmenting the target nucleic acid so that the mode value of the nucleic acid length falls within the range of 100 to 1500 bases is hybridized with the capture probe (1) to (5 ) Any one of the methods.
  • a human-derived specimen containing the target nucleic acid is subjected to the detection method, and the detection method further comprises a step of detecting at least one repetitive sequence present in the human genome as an internal standard, the repetitive sequence Is the method according to any one of (1) to (7), which is contained in a human genome fragment.
  • the method according to (8) or (9), wherein the repetitive sequence is a short-dispersed nuclear repeat sequence.
  • the short-dispersed nuclear repeat sequence is an Alu sequence.
  • nucleic acid detection can be performed with high sensitivity without using nucleic acid amplification or sensitization techniques such as PCR.
  • FIG. 2 is a diagram conceptually showing positions of a capture probe and a detection probe in Example 1.
  • FIG. It is a figure which shows notionally the position of the capture probe and detection probe in Example 2.
  • FIG. It is a conceptual diagram of the sandwich hybrid in a mutation analysis. It is a figure which shows notionally the position of the k-ras mutation capture probe and the detection probe in Example 3 and Example 4. It is a figure which shows notionally the position of the EGFR mutation capture probe and the detection probe in Example 3 and Example 4. It is a figure which shows typically embodiment which performs the method of this invention using the Alu sequence in the human genome contained in the sample derived from a human as an internal standard.
  • target nucleic acid used in the detection method of the present invention examples include, but are not limited to, genes such as pathogenic bacteria and viruses, causative genes of genetic diseases, and the like, and parts thereof.
  • Samples containing these target nucleic acids include body fluids such as blood, serum, plasma, urine, feces, spinal fluid, saliva, wipes, various tissue fluids, various tissues, paraffin-embedded samples (FFPE), and sections thereof.
  • body fluids such as blood, serum, plasma, urine, feces, spinal fluid, saliva, wipes, various tissue fluids, various tissues, paraffin-embedded samples (FFPE), and sections thereof.
  • FFPE paraffin-embedded samples
  • the target nucleic acid to be the test substance may be a sample nucleic acid extracted from blood or cells by a conventional method, and DNA or RNA extracted from the sample can be used.
  • DNA examples include, but are not limited to, chromosomal DNA, viral DNA, bacteria and mold DNA, cDNA obtained by reverse transcription of RNA, and fragments that are a part of them.
  • RNA messenger RNA, ribosomal RNA, small RNA, a fragment that is a part thereof, and the like can be used, but are not limited thereto.
  • chemically synthesized DNA or RNA can be used as the target nucleic acid.
  • the sample nucleic acid may contain a nucleic acid component (non-target nucleic acid) other than the target nucleic acid to be measured.
  • non-target nucleic acids may be removed in consideration of the difference in properties from the target nucleic acid, or may be used as a test substance without being removed.
  • the target nucleic acid may be amplified by a nucleic acid amplification method such as PCR using the target nucleic acid as a template, and the measurement sensitivity can be greatly improved.
  • a nucleic acid amplification product is used as a target nucleic acid
  • the amplified nucleic acid can be labeled by performing amplification in the presence of a nucleoside triphosphate labeled with a fluorescent substance or the like.
  • the present invention it is possible to detect a target nucleic acid with sufficient sensitivity without using a nucleic acid amplification method, and when using the nucleic acid amplification method, there is a problem of false positives and troublesome operations. Therefore, the present invention is particularly effective when applied to a target nucleic acid that has not been amplified by the nucleic acid amplification method or a fragmented product thereof.
  • the method of the present invention comprises detection of the presence or absence of a target nucleic acid, virus genotype, bacterial species and strain, mold species and strain, etc., detection of SNP (single nucleotide polymorphism), detection of messenger RNA, miRNA It can be used for detection, detection of CGH, copy number variation, genomic DNA sequence deletion / duplication / fusion, or transcription product deletion / duplication / fusion. It can also be applied to quantification of target nucleic acids by measuring the signal intensity from the detection probe. In addition, since the target nucleic acid is inevitably detected when the target nucleic acid is quantified, the “detection method” of the present invention includes the case where the quantification is accompanied.
  • the target nucleic acid can be applied as it is, or a fragmented product of the target nucleic acid can be applied.
  • the target nucleic acid is long (1500 bases or more, particularly 4000 bases or more)
  • the fragmented product does not need to select a specific nucleic acid fragment from the resulting nucleic acid fragments, and the fragmented product can be directly used in the method of the present invention, thereby improving the detection sensitivity.
  • Methods for cleaving the target nucleic acid for fragmentation include methods of cleaving with ultrasonic waves, methods of cleaving with enzymes, methods of cleaving with restriction enzymes, methods using a nebulizer, methods of cleaving with acids and alkalis, etc. Can be used.
  • the method of cutting with ultrasonic waves it is possible to cut to a desired length by controlling the output intensity and irradiation time of the ultrasonic waves irradiated to the target nucleic acid.
  • the degree of fragmentation of the treated target nucleic acid can be analyzed using analysis means such as electrophoresis described below. As a result of the analysis, if the ultrasonic treatment is insufficient, the ultrasonic treatment can be further performed until the target nucleic acid under desired conditions is obtained.
  • the ultrasonic processing apparatus include an acoustic solver (Covalis), a bioraptor (Tojo Electric), and an ultrasonic type homogenizer (Tytec Corp., VP-050). By setting four parameters of Duty Factor, Peak ⁇ ⁇ incident power, ⁇ Cycles per burst, and time, Cobaris acoustic solver S220 can be cut to a desired length.
  • a nucleic acid fragment having a desired length can be obtained by adjusting the heating time using dSDNA shearase (Zymo Research) or a restriction enzyme.
  • dSDNA shearase Zymo Research
  • the manufacturer's recommended heating time may be followed.
  • the length of the cut fragment can be controlled by adjusting the treatment conditions.
  • the fragmented target nucleic acid can be evaluated using the mode value of the nucleic acid length as an index.
  • the mode value of the nucleic acid length refers to a peak top value obtained by subjecting a fragmented nucleic acid to electrophoresis using an agarose gel electrophoresis or a bioanalyzer (Agilent, DNA7500 kit, RNA 6000 nano kit).
  • the electrophoretic result is displayed as an electropherogram, the highest position of the waveform is defined as the peak top, and the value of the intersection of the perpendicular drawn from the peak top and the x axis is defined as the mode value of the nucleic acid length.
  • FIG. 2A is an agarose gel electrophoresis image of the ladder marker and the cleaved nucleic acid.
  • image processing software such as NIH Image (NIH)
  • this image is displayed as a waveform.
  • the distance from the origin of electrophoresis is obtained for each ladder marker.
  • the distance to the peak top that is, the portion with the highest luminance is obtained.
  • the mode value of the cleaved target nucleic acid can be obtained.
  • the mode value of the nucleic acid length of the cleaved target nucleic acid used in FIG. 2 is 158 bases.
  • the shape of the waveform may be any shape, but sharper is more preferable than broad.
  • a cleaved fragment having a mode value of a desired nucleic acid length is obtained by the above-mentioned various methods.
  • a preferable range of the mode of the nucleic acid length is between 100 bases and 1500 bases.
  • a more preferred range is 250 to 500 bases.
  • the mode of the nucleic acid length can be evaluated by performing a fragmentation process in the same manner as described above.
  • the support can be a glass slide, a membrane, beads or the like.
  • the material of the support is not particularly limited, and examples thereof include inorganic materials such as glass, ceramic and silicon, and polymers such as polyethylene terephthalate, cellulose acetate, polycarbonate, polystyrene, polymethyl methacrylate and silicone rubber.
  • the support is preferably not an optical planar waveguide.
  • the capture probe means a substance that can selectively bind directly to a target nucleic acid contained in a test sample.
  • nucleic acid derivatives such as DNA, RNA, PNA, and LNA (Locked Nucleic Acid) can be used.
  • a derivative is a labeled derivative by a fluorophore or the like, a modified nucleotide (for example, halogen, an alkyl such as methyl, an alkoxy such as methoxy, a nucleotide or a base containing a group such as thio, carboxymethyl, Chemically modified derivatives such as derivatives containing nucleotides etc. that have undergone double bond saturation, deamination, substitution of oxygen molecules with sulfur molecules, and the like.
  • a modified nucleotide for example, halogen, an alkyl such as methyl, an alkoxy such as methoxy, a nucleotide or a base containing a group such as thio, carboxymethyl
  • Chemically modified derivatives such as derivatives containing nucleotides etc. that have undergone double bond saturation, deamination, substitution of oxygen molecules with sulfur molecules, and the like.
  • a single-stranded nucleic acid having a specific base sequence selectively hybridizes and binds to a single-stranded nucleic acid having a base sequence complementary to the base sequence or a part thereof, it is used as a capture probe in the present invention.
  • the capture probe used in the present invention may be a commercially available probe or a probe obtained from a living cell. Particularly preferred as a capture probe is a nucleic acid.
  • nucleic acids called oligonucleic acids having a length of up to 200 bases can be easily artificially synthesized with a synthesizer.
  • the capture probe only needs to contain a sequence complementary to the target nucleic acid sequence, and any region may be selected. It is preferable that it does not overlap with the sequence of the detection probe described below. A plurality of types of capture probes that hybridize with different regions of the target nucleic acid can also be used. However, according to the method of the present invention, satisfactory detection sensitivity can be obtained even if there is only one type of capture probe, so it is simple and preferable that there is one type of capture probe for each target nucleic acid.
  • a sequence complementary to any one of the Watson strand (sense strand) and the click strand (antisense strand) can be selected as a capture probe.
  • the detection probe and the capture probe described below preferably select the same strand sequence.
  • the specificity is selected from the nucleic acid sequences that can be contained in the sample nucleic acid, for example, by distinguishing and detecting the type of virus infecting the patient. It is preferable to select a high sequence region. That is, the sequence selected as the capture probe means that there is no highly homologous sequence other than the region in all sequences included in the sample nucleic acid.
  • the method proposed in Patent Document 3 can be used for the design of a capture probe that can be used for detection of a single nucleotide polymorphism. Specifically, a base suspected of being mutated is placed in the center of the capture probe, and 10 bases before and after that are added to form a capture probe having a total length of 21 bases. A capture probe in which A is placed in a base part suspected of mutation, a capture probe in which T is placed in a base part suspected of mutation, a capture probe in which G is placed in a base part suspected of mutation, and a base in which a mutation is suspected A capture probe in which C is arranged in the portion can be used as a capture probe set (FIG. 5).
  • the homology (%) can be determined using a homology search program (for example, BLAST, FASTA, etc.) commonly used in this field by default.
  • the homology (%) is determined by any algorithm known in the art, such as Needleman et al. (1970) (J. Mol. Biol. 48: 444-453), Myers and Miller (CABIOS, 1988, 4: 11-17) and the like. Needleman et al.'S algorithm is incorporated into the GAP program of the GCG software package (available at www.gcg.com), and the homology (%) is, for example, BLOSUM 62 matrix or PAM250 matrix, and gap weight: 16, 14, 12, 10, 8, 6 or 4 and length weight: 1, 2, 3, 4, 5 or 6 can be used.
  • the Myers and Miller algorithms are also incorporated into the ALIGN program that is part of the GCG sequence alignment software package.
  • Detecting probe means a substance that can directly bind to a target nucleic acid contained in a test sample.
  • nucleic acid derivatives such as DNA, RNA, PNA, and LNA (Locked Nucleic Acid) can be used.
  • a derivative is a labeled derivative by a fluorophore or the like, a modified nucleotide (for example, a halogen or an alkyl such as methyl, an alkoxy such as methoxy, a nucleotide or a base containing a group such as thio or carboxymethyl, Chemically modified derivatives such as derivatives containing nucleotides etc. that have undergone double bond saturation, deamination, substitution of oxygen molecules with sulfur molecules, and the like.
  • a modified nucleotide for example, a halogen or an alkyl such as methyl, an alkoxy such as methoxy, a nucleotide or a base containing a group such as thio or carboxymethyl
  • Chemically modified derivatives such as derivatives containing nucleotides etc. that have undergone double bond saturation, deamination, substitution of oxygen molecules with sulfur molecules, and the like.
  • a single-stranded nucleic acid having a specific base sequence selectively hybridizes and binds to a single-stranded nucleic acid having a base sequence complementary to the base sequence or a part thereof.
  • the detection probe used in the present invention may be a commercially available probe or a probe obtained from a living cell. Particularly preferred as a detection probe is a nucleic acid.
  • nucleic acids called oligonucleic acids having a length of up to 200 bases can be easily artificially synthesized with a synthesizer.
  • a sequence complementary to either the Watson strand or the click strand can be selected as a detection probe. It is preferable to select the same strand sequence for the capture probe and the detection probe described above.
  • the detection probe only needs to contain a sequence complementary to the target nucleic acid sequence, and any region may be selected. However, it is preferable that the sequence does not overlap with the capture probe sequence described above. Furthermore, it is preferable to select a sequence within a range of 1500 bases from the capture probe design position.
  • the sequence of the detection probe is preferably low in homology with the capture probe and preferably has a homology of 80% or less, but can be determined in consideration of stringency during hybridization.
  • the stringency during hybridization is a function of temperature, salt concentration, probe chain length, GC content of the probe nucleotide sequence, and the concentration of the chaotropic agent in the hybridization buffer.
  • the conditions described in Sambrook, J. et al. (1998) Molecular Cloning: A Laboratory Manual (2nd ed.), Cold Spring Harbor Laboratory Press, New York can be used. .
  • Stringent temperature conditions are about 30 ° C. or higher.
  • Other conditions include the hybridization time, the concentration of the detergent (for example, SDS), the presence or absence of carrier DNA, and various stringencies can be set by combining these conditions.
  • a person skilled in the art can appropriately determine conditions for obtaining a function as a capture probe prepared for detection of a desired target nucleic acid and a detection probe.
  • a sequence having 100% homology among target nucleic acids to be detected can be used as a common detection probe.
  • the common detection probe may use a degenerate sequence when the homology between the target nucleic acids to be detected is not 100%.
  • “Bio-Experiment Illustrated Really PCR” (1999), edited by Hiroki Nakayama, published by Shujunsha Co., Ltd., pages 121-125 can be referred to.
  • a label can be bound to the detection probe.
  • a label can be bound to either the 5 ′ end, the 3 ′ end, or both. It is also possible to introduce a label into the detection probe.
  • a chemical reaction, an enzyme reaction, etc. can be used for the binding of the label. Preferably, the reaction is performed using a chemical reaction. More preferably, when the detection probe is chemically synthesized, a label is bound to the end. A label can also be bound to the inside of the detection probe.
  • a chemical reaction can be used for binding of the label, and a biotin label can be inserted by a synthesizer. Biotin-TEG, Biotin-ON, and Biotin-dT can be inserted (https://www.operon.jp/index.php).
  • a label that can be used a known substance used for labeling such as a protein-binding substance, a fluorescent dye, a phosphorescent dye, and a radioisotope can be used. Preference is given to protein binding substances.
  • An example of a protein binding substance is biotin. Biotin can bind to avidin or streptavidin. Avidin or streptavidin bound with a fluorescent dye, or bound with an enzyme such as alkaline phosphatase or horseradish peroxidase can be used. When alkaline phosphatase or horseradish peroxidase is used, each substrate is added and the substrate reacts with the enzyme, resulting in a luminescence reaction.
  • the luminescence reaction is detected using a plate reader or a CCD camera.
  • a label conventionally used in this field and a special label such as a label that provides a signal that can be detected by evanescent excitation luminescence.
  • the label is preferably not a label that provides a signal that can be detected by evanescent excitation luminescence.
  • a fluorescent dye that is easy to measure and easily detects a signal may be used.
  • cyanine cyanine 2
  • aminomethylcoumarin fluorescein
  • indocarbocyanine cyanine 3
  • cyanine 3.5 aminomethylcoumarin
  • fluorescein indocarbocyanine
  • cyanine 3.5 tetramethylrhodamine
  • rhodamine red Texas red
  • indocarbocyanine cyanine 5
  • cyanine 5.5 known fluorescent dyes such as cyanine 7, oyster, BODIPY dye, and phycoerythrin.
  • a semiconductor fine particle having a light emitting property may be used as a marker.
  • semiconductor fine particles include cadmium selenium (CdSe), cadmium tellurium (CdTe), indium gallium phosphide (InGaP), chalcopyrite fine particles, and silicon (Si).
  • the fluorescent dye can be detected with a fluorescent microscope or a fluorescent scanner.
  • Detected signal is compared with ambient noise. Specifically, it is assumed that the signal value obtained from the position where the capture probe is fixed is compared with the signal value obtained from other positions, and the case where the former value is detected is detected.
  • a method for immobilizing a capture probe on a support there are known a method of synthesizing oligo DNA on the upper surface of the support and a method of dropping and immobilizing pre-synthesized oligo DNA on the upper surface of the support.
  • the former method includes the method of Ronald et al. (US Pat. No. 5,705,610), the method of Michel et al. (US Pat. No. 6,142,266), and the method of Francesco et al. (US Pat. No. 7,037,659).
  • the carrier is preferably made of a material resistant to the organic solvent.
  • a glass carrier having a concavo-convex structure produced by using the method described in JP-T-10-503841 can be used.
  • the carrier is preferably made of a light-transmitting material.
  • the method of Hirota et al. Japanese Patent No. 3922454
  • a glass capillary can be used.
  • the glass capillary As an example of the glass capillary, a commercially available product such as a self-made glass capillary or a micropipette (manufactured by Micro Support Co., Ltd .; MP-005) can be used, but it is not limited to these methods.
  • a commercially available product such as a self-made glass capillary or a micropipette (manufactured by Micro Support Co., Ltd .; MP-005) can be used, but it is not limited to these methods.
  • Preparation of DNA or RNA from living cells can be carried out by a known method, for example, by the method of Blin et al. (Blin et al., Nucleic Acids Res. 3 2303 (1976)), etc. Extraction can be performed by the method of Favaloro et al. (Favaloro et.al., Methods Enzymol.65: 718 (1980)).
  • the nucleic acid to be immobilized include linear or circular plasmid DNA and chromosomal DNA, DNA fragments obtained by digesting these with restriction enzymes or chemically, DNA synthesized with enzymes in a test tube, or chemically synthesized oligos. Nucleotides and the like can also be used.
  • the method of the present invention is sandwich hybridization, the basic operation itself is the same as that of known sandwich hybridization. That is, a target nucleic acid or fragmented product thereof, a plurality of detection probes, and a capture probe immobilized on a support are brought into contact sequentially or simultaneously to hybridize the capture probe and the target nucleic acid or fragmented product thereof. And the target nucleic acid or fragmented product thereof is hybridized with the plurality of detection probes, whereby the plurality of detection probes are passed through the capture probe and the target nucleic acid or fragmented product thereof. Then, the plurality of detection probes bound to the support are detected.
  • the step of sequentially or simultaneously bringing the target nucleic acid or fragmented product thereof into contact with the plurality of detection probes and the capture probe immobilized on the support comprises (1) first the target nucleic acid or fragmented product thereof, and a plurality of fragments.
  • the target nucleic acid hybridized with a plurality of detection probes or a fragmented product thereof may be brought into contact with the capture probe immobilized on the support and hybridized.
  • the target nucleic acid or fragmented product thereof is first contacted with the capture probe immobilized on the support and hybridized, and then the target nucleic acid hybridized with the capture probe or the target nucleic acid
  • the fragmented product and a plurality of detection probes may be brought into contact with each other and hybridized.
  • the target nucleic acid or a fragmented product thereof, a plurality of detection probes, and a support are fixed.
  • the capture probe and the target nucleic acid or fragmented product thereof are hybridized by contacting the captured probe simultaneously, and the target nucleic acid or fragmented product thereof and the plurality of detection probes are hybridized.
  • the method of sequentially contacting by the above method (1) is preferable because the detection sensitivity often increases.
  • Each hybridization step can be performed in the same manner as in the past.
  • the reaction temperature and time are appropriately selected according to the chain length of the nucleic acid to be hybridized. In the case of nucleic acid hybridization, it is usually about 30 ° C. to 70 ° C. for 1 minute to several tens of hours. Is usually from room temperature to about 40 ° C. for about 1 minute to several hours.
  • detection is performed using a target nucleic acid having a total length of 3000 bases.
  • the capture probe may be designed in any part of the target nucleic acid, but in this example, the sequence from the beginning of the target nucleic acid to the 2200 to 2230 bases was used as the sequence to which the capture probe binds.
  • Four detection probes were designed in a region included in the range of 1500 bases from the region where the capture probe binds. Each detection probe and sequence region are as follows. Detection probe 1: 2000th to 2019th base, detection probe 2: 2100th to 2119th base, detection probe 3: 2319th to 2330th base, detection probe 4: 2419th to 2430th base.
  • the distance from the capture probe is determined by arranging the capture probe binding position and the detection probe binding position on the target nucleic acid sequence, and counting the number of bases between them with the farthest base as the end. This will be described using the example of FIG. 1B.
  • the distance between the detection probe 2: 2100 bases to 2119 bases and the capture probe: 2200 bases to 2230 bases is counted from the position of the farthest base as an end, so the distance is 131 bases.
  • the distance between the detection probe 3: 2319th base to 2330th base and the capture probe: 2200th base to 2230th base is counted with the position of the farthest base as an end, so the distance is 131 bases.
  • the distance between the detection probes 1 and 4 and the capture probe is 231 bases.
  • the target nucleic acid is cleaved so that the mode of the nucleic acid is 250 bases.
  • Schematic diagrams in which this target nucleic acid, detection probes 1, 2, 3, 4 and a capture probe are hybridized are shown in FIGS. 1A, 1B, and 1C.
  • FIG. 1A shows the form of hybridization of a fragment in which the target nucleic acid has been cleaved after the 2231st base.
  • the detection probe 1 and the detection probe 2 can bind to the target nucleic acid.
  • FIG. 1B shows the form of hybridization of a fragment in which the target nucleic acid was cleaved before the 2100th base and after the 2330th base.
  • the detection probe 2 and the detection probe 3 can bind to the target nucleic acid.
  • FIG. 1C shows the form of hybridization of a fragment in which the target nucleic acid was cleaved before the 2200th base and after the 2430th base.
  • the detection probe 3 and the detection probe 4 can be bound to the target nucleic acid.
  • the detection probes 2 and 3 can be bound to the target nucleic acid bound to the capture probe. Therefore, the detection sensitivity is lowered.
  • the detection probe is designed on both sides of the capture probe. However, the detection probe may be only on the 3 ′ end side or only on the 5 ′ end side of the capture probe.
  • an internal standard is also detected at the same time in order to confirm whether or not the detection method itself has been performed correctly. That is, when the target nucleic acid is not detected by the detection method, it cannot be determined whether the target nucleic acid is not present in the test sample or whether the detection method is not performed correctly. For this reason, a nucleic acid region that is universally present in the test sample is used as an internal standard, and if this internal standard is detected, the detection method is judged to have been performed correctly. If no internal standard is detected, the detection method is correct. Judging that it was not done is done. When the test sample is derived from a human, actin or globin is generally used as an internal standard.
  • an actin gene or globin gene can be used as an internal standard.
  • an actin gene or globin gene can be used as an internal standard.
  • a target nucleic acid or a fragmented product thereof is amplified by PCR or the like, Similar internal standards can be used without problems.
  • the detection method of the present invention is a method that exhibits an excellent effect that the target nucleic acid can be detected with sufficient sensitivity without performing the nucleic acid amplification method. If the nucleic acid amplification method is not performed, the actin gene and globin gene have only one copy in the genome, so the sensitivity is insufficient, and the internal standard may not be detected even though the detection method is performed correctly. .
  • a specimen derived from an animal such as a human containing the target nucleic acid is subjected to the detection method, and at least one repetitive sequence present in the animal genome is internally contained. Amplify as standard. This repetitive sequence is contained in the animal genome fragment.
  • the animal genome fragment may be generated by fragmentation processing of the animal genome, or may be a fragment generated naturally.
  • the preferred length of the genomic fragment is the same as the preferred length of the target nucleic acid or fragmented product thereof.
  • animals humans; pets such as dogs and cats; domestic animals such as pigs, cows, horses, sheep and goats; mammals such as laboratory animals such as monkeys, mice and rats are preferred, and humans are particularly preferred, but these are repeated.
  • a retrotransposon particularly a short interspersed nuclear repeat sequence (SINE) is preferable, and in particular, an Alu sequence present in 1 million copies in the human genome is preferable.
  • SINE short interspersed nuclear repeat sequence
  • Alu sequence itself is a known sequence, and its base sequence is also known (SEQ ID NO: 47).
  • FIG. 8 is a conceptual diagram for explaining the principle of the method of the present invention when the target nucleic acid is viral DNA and a human-derived specimen containing a human genome is used for the detection method.
  • a human Alu sequence is used as an internal standard.
  • a human Alu sequence capture probe that complements the Alu sequence was immobilized on a support, and multiple types of human Alu sequence detection probes that detect the captured human DNA were hybridized with the captured human Alu sequence and captured. Human Alu sequence is detected.
  • the detection of animal DNA such as a human Alu sequence can be performed in the same manner as the above-described method for detecting a target nucleic acid or a fragmented product thereof, and preferable conditions are also the same as above.
  • Example 1 The present invention will be described in more detail by way of an example of human papillomavirus detection as an example of distinguishing and detecting the type of virus infecting a patient. However, the present invention is not limited to the following examples.
  • Human papillomavirus is known as a causative virus for cervical cancer. There are over 100 types of human papillomavirus, and among them, there are 13 types with high malignancy that cause cervical cancer. In preventive medicine for cervical cancer, knowing which type of virus a subject is infected with is important information for considering a treatment policy. Human papillomavirus typing is performed from the cervical wiping fluid. Hybrid capture methods, PCR methods and the like are known. By applying the present invention to the detection of human papillomavirus, the type of virus in which the subject is infected can be identified with high sensitivity.
  • the design position of the capture probe is located in almost the same region of the L1 gene regardless of the type.
  • the common primer is used as a common detection probe so that the distance from the capture probe is almost the same between the molds (FIG. 3).
  • Table 2 The capture probe having the above sequence was synthesized by Operon with a synthetic DNA having an amino group modified at the 5 ′ end.
  • the detection probe was synthesized by Operon with 3 'end and 5' end labeled with biotin.
  • a DNA chip is prepared by immobilizing all of the capture probes in Table 1 on the substrate of the DNA chip “3D-Gene” (registered trademark) (http://www.3d-gene.com/en/products/pro_009.html). did. Details are described below.
  • a mold for injection molding was prepared using a known method LIGA (Lithographie Galvanoformung Abformung), and a carrier made of PMMA having a shape as described later was obtained by the injection molding method. Carbon black (Mitsubishi Chemical Corporation, # 3050B) is contained in PMMA at a ratio of 1% by weight, and the carrier is black.
  • the shape of the carrier was 76 mm in length, 26 mm in width, and 1 mm in thickness, and the surface was flat except for the central part of the carrier. In the center of the carrier, a recessed portion having a diameter of 10 mm and a depth of 0.2 mm is provided.
  • convex portions having a diameter of 0.2 mm and a height of 0.2 mm are provided.
  • the pitch of the concavo-convex convex portions was 0.6 mm.
  • the capture probe DNA shown in Table 1 was dissolved in pure water at a concentration of 0.3 nmol / ⁇ L to obtain a stock solution.
  • PBS NaCl 8 g, Na 2 HPO 4 ⁇ 12H 2 O 2.9 g, KCl 0.2 g, KH 2 PO 4 0.2 g in pure water was made up to 1 L.
  • KCl 0.2 g, KH 2 PO 4 0.2 g in pure water was made up to 1 L.
  • a final concentration of the probe DNA 0.03 nmol / ⁇ L.
  • pHPV16 As a sample DNA, a recombinant plasmid pHPV16 in which genomic DNA of human papillomavirus was cloned was purchased from Human Science Research Resource Bank and used. pHPV16 was 16,600 base pairs in length. If the molecular weight of one base pair is 680, 1 ⁇ g is 89 nmol.
  • the method for preparing the sample DNA is shown below.
  • 1 ⁇ g of pHPV16 was fragmented by sonication (Covaris, s220).
  • the fragmentation treatment conditions were set to 100 bases, 150 bases, 250 bases, 400 bases, 1500 bases, and 4000 bases according to the method recommended by the manufacturer.
  • Fragment length was evaluated using a bioanalyzer (Agilent), and the peak tops of fragmented nucleic acids obtained under each treatment condition were 100 bases, 150 bases, 250 bases, 400 bases, 1500 bases, 4000 bases. Met.
  • the concentration of the cleaved sample DNA was measured using a nanodrop (Thermo Fisher, ND-1000) to determine the concentration of the nucleic acid. From the nucleic acid concentration, the cleaved DNA contained in each cleaved solution was diluted with 1 ⁇ hybridization solution to 1 ⁇ amol / ⁇ L, and used as sample DNA.
  • the detection probe was diluted with sterilized water to a concentration of 100 fmol / ⁇ L. Even when a plurality of detection probes were mixed, they were similarly diluted with sterilized water so that the concentration of each detection probe was 100 fmol / ⁇ L.
  • Hybridization 1 ⁇ L of the diluted detection probe solution was mixed with 5 ⁇ L of the sample DNA, and heated at 95 ° C. for 5 minutes using a thermal cycler. After heating, it was left on the desk for 2 minutes until it returned to room temperature.
  • a 1 ⁇ hybridization solution (1 wt% BSA (bovine serum albumin), 5 ⁇ SSC, 1 wt% SDS (sodium dodecyl sulfate), 50 ng / ml salmon sperm DNA solution, 5 wt% dextran sodium sulfate, 30 % Formamide) was added to give a hybrid solution. The entire amount was injected into a DNA chip and set in an incubator heated at 32 ° C.
  • Hybridization was performed at 32 ° C. for 2 hours while swirling at 250 rpm according to the standard protocol of “3D-Gene”. After hybridization, the DNA chip was washed with a washing solution (0.5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate)) heated to 30 ° C. for 5 minutes, and then using a spin dryer (Wakken Yakuhin). Dried.
  • a washing solution 0.5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate)
  • a solution in which streptavidin phycoerythrin (Prozyme) was added to a staining solution 50 ng / ⁇ l streptavidin phycoerythrin, 100 mM MES, 1 M NaCl, 0.05 wt% Tween 20, 2 mg / ml BSA (bovine serum albumin) was prepared and dropped on a DNA chip. Incubated at 35 ° C. for 5 minutes. After washing with a washing liquid (6XSSPE, 0.01 wt% Tween 20) heated to 30 ° C. for 5 minutes, it was dried using a spin dryer (Wakken). For the stained DNA chip, a fluorescent signal was detected using a DNA chip scanner (Toray). The scanner was set to 100% laser output and 70% photomultiplier voltage.
  • Table 3 shows the detection results. From the results of mixing and detecting four types of detection probes, it can be seen that when the sample is not cleaved, the detection signal is significantly improved in the sample cleaved to 1500 bases or less, compared to the case of cleaving to 4000 bases. In particular, the sensitivity is highest at 250 bases and 500 bases, and it can be seen that the sensitivity starts to decrease when the base is further cut.
  • MY11 is a detection probe designed 340 bases away from the capture probe.
  • MY09 is a detection probe designed 340 bases away from the capture probe.
  • the sum of the signal intensities obtained by the individual detection probes is equivalent to the signal intensity when the four kinds are mixed and used.
  • the sum of signal intensities obtained with the individual detection probes is shown at the bottom of Table 3.
  • the target nucleic acid is cleaved to 1500 bases or less
  • the signal intensity when used in a mixture of four types shows a very large value. This was presumed that the hybridization between the capture probe and the target nucleic acid was enhanced by the binding of a plurality of detection probes.
  • Example 2 The invention is described in further detail by another embodiment of human papillomavirus detection. However, the present invention is not limited to the following examples.
  • pHPV16 As a sample DNA, a recombinant plasmid pHPV16 in which genomic DNA of human papillomavirus was cloned was purchased from Human Science Research Resource Bank and used. pHPV16 was 16,600 base pairs in length. If the molecular weight of one base pair is 680, 1 ⁇ g is 89 nmol.
  • the method for preparing the sample DNA is shown below. 5 ⁇ g of pHPV16 was fragmented by sonication (Covaris, s220). The fragmentation treatment conditions were set to 150 bases and 250 bases according to the method recommended by the manufacturer. The length of the fragment was evaluated using a bioanalyzer (Agilent), and the peak top of the fragmented nucleic acid obtained under each treatment condition was 150 bases and 250 bases. The concentration of the cleaved sample DNA was measured using a nanodrop (Thermo Fisher, ND-1000) to determine the concentration of the nucleic acid. From the nucleic acid concentration, the cleaved DNA contained in each cleaved solution was diluted with 1 ⁇ hybridization solution to 1 ⁇ amol / ⁇ L, and used as sample DNA.
  • the detection probe was diluted with sterilized water to a concentration of 100 fmol / ⁇ L. Even when a plurality of detection probes are mixed and used, the concentration of each detection probe was similarly diluted with sterile water so as to be 100 fmol / ⁇ L.
  • Hybridization 1 ⁇ L of the diluted detection probe solution was mixed with 5 ⁇ L of the sample DNA, and heated at 95 ° C. for 5 minutes using a thermal cycler. After heating, it was left on the desk for 2 minutes until it returned to room temperature.
  • a hybridization solution 1X hybridization solution (1 wt% BSA (bovine serum albumin), 5 ⁇ SSC, 1 wt% SDS (sodium dodecyl sulfate), 50 ng / ml salmon sperm DNA solution, 5 wt% dextran sulfate 35 ⁇ L of sodium, 30% formamide) was added to obtain a hybrid solution.
  • the entire amount was injected into a DNA chip and set in an incubator heated at 32 ° C. Hybridization was performed at 32 ° C. for 2 hours while swirling at 250 rpm according to the standard protocol of “3D-Gene”. After hybridization, the DNA chip was washed with a washing solution (0.5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate)) heated to 30 ° C. for 5 minutes, and then using a spin dryer (Wakken Yakuhin). Dried.
  • a washing solution 0.5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate)
  • a solution in which streptavidin phycoerythrin (Prozyme) was added to a staining solution 50 ng / ⁇ l streptavidin phycoerythrin, 100 mM MES, 1 M NaCl, 0.05 wt% Tween 20, 2 mg / ml BSA (bovine serum albumin) was prepared and dropped on a DNA chip. Incubated at 35 ° C for 5 minutes. The plate was washed with a washing solution (6XSSPE, 0.01 wt% Tween 20) heated to 30 ° C. for 5 minutes and then dried using a spin dryer (Wakken). For the stained DNA chip, a fluorescent signal was detected using a DNA chip scanner (Toray). The scanner was set to 100% laser output and 70% photomultiplier voltage.
  • Table 5 shows the detection results. From the result of detection by mixing five types of detection probes (mixing five types), the signal intensity of 250 bases is higher than that of 150 bases. Two detection probes are effective when cleaved to 150 bases, whereas three detection probes are effective when cleaved to 250 bases. It can be said that the difference in signal intensity was caused by the difference in the number of detection probes that could be bound. On the other hand, comparing the results of detection of the target nucleic acid cleaved to 250 bases in a mixture of four types and a mixture of five types, the signal intensity is higher in the mixture of five types. This is two effective detection probes in the case of using the four-type mixture, but three in the case of the five-type mixture. It can be said that the difference in signal intensity was caused by the difference in the number of detection probes that could be bound.
  • a particularly sufficient signal intensity can be obtained by preparing a plurality of detection probes and cleaving the target nucleic acid in consideration of the binding region of the detection probes.
  • the target nucleic acid is preferably cleaved to around 400 bases (about ⁇ 50 bases), and further to 400 bases.
  • Example 3 The present invention will be described in more detail by detecting SNPs (single nucleotide polymorphisms). However, the present invention is not limited to the following examples.
  • SNPs single nucleotide polymorphisms
  • the response rate of anticancer drugs varies depending on the presence or absence of mutations in the EGFR gene or k-ras gene, which is a criterion for determining anticancer drug administration.
  • detection is performed using various methods after amplification by PCR.
  • a capture probe for SNP detection places the SNP site in the center of the probe. Specifically, 10 bases before and after the SNP site are used as a capture probe sequence. In the case of SNP detection, the capture probe prepares a combination of all bases at the SNP site and uses it as a capture probe set. Specifically, in the case of the SNP site of wild type: G, mutant type: A, 21 bases including 10 bases before and after G or A are used as capture probes. For comparison purposes, the center part of the probe is set to T or C, and 21 bases including 10 bases before and after are used as capture probes. The above 4 sequences are used as a capture probe set. Thus, a capture probe set for Gly12Ser, Gly12Arg, Gly12Cys, and T790M, which are EGFR mutations, was prepared (Table 6).
  • the detection probe was designed at the position shown in FIGS. 6 and 7 in consideration of the distance from the design of the capture probe.
  • Tables 7 and 8 show the sequences of the detection probes and the distances from the capture probes.
  • a synthetic DNA having an amino group modification at the 5 ′ end was synthesized by Operon.
  • the detection probe was synthesized by Operon with 3 'end and 5' end labeled with biotin.
  • A549 cells are cultured cells derived from lung cancer tissue, and are known to contain a Gly12Ser mutation.
  • 5 ⁇ g of DNA extracted from A549 cells was fragmented by sonication (Covaris, s220). The fragmentation processing conditions followed the manufacturer's recommended method. The length of the fragments was evaluated using a bioanalyzer (Agilent). The mode value of the nucleic acid length was 750 bases. The total amount of the cleaved DNA was used as the sample DNA.
  • Hybridization 1 ⁇ L of the diluted detection probe solution was mixed with 5 ⁇ L of the sample DNA, and heated at 95 ° C. for 5 minutes using a thermal cycler. After heating, it was left on the desk for 2 minutes until it returned to room temperature. To this solution, 35 ⁇ L of a hybridization solution (composition confirmation: 1 wt% BSA (bovine serum albumin), 5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate), 0.01 wt% salmon sperm DNA solution) In addition, a hybrid solution was obtained. The entire amount was injected into a DNA chip and set in an incubator heated at 32 ° C. Hybridization was performed at 32 ° C.
  • BSA bovine serum albumin
  • SSC sodium dodecyl sulfate
  • the DNA chip was washed with a washing solution (0.5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate)) heated to 30 ° C. for 5 minutes, and then using a spin dryer (Wakken Yakuhin). Dried.
  • a washing solution 0.5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate)
  • a solution in which streptavidin phycoerythrin (Prozyme) was added to a staining solution 50 ng / ⁇ l streptavidin phycoerythrin, 100 mM MES, 1 M NaCl, 0.05 wt% Tween 20, 2 mg / ml BSA (bovine serum albumin) was prepared and dropped on a DNA chip. Incubated at 35 ° C for 5 minutes. The plate was washed with a washing solution (6XSSPE, 0.01 wt% Tween 20) heated to 30 ° C. for 5 minutes and then dried using a spin dryer (Wakken). For the stained DNA chip, a fluorescent signal was detected using a DNA chip scanner (Toray). The scanner was set to 100% laser output and 70% photomultiplier voltage.
  • Table 9 shows the detection results.
  • the wild-type probe since the wild-type probe has the highest signal intensity, it is considered that the T790M mutation does not occur in A549 cells.
  • the signal intensity of the Gly12Ser probe is the highest.
  • A549 cells are known to contain the Gly12Ser mutation, which was consistent with the present detection results.
  • SNPs could be detected correctly without PCR amplification by using sandwich hybrids.
  • Example 4 The K-ras gene mutation and EGFR gene mutation shown in Example 3 are important indicators of anticancer drug administration, but it is also important to confirm the presence or absence of their gene expression by another method.
  • RNA can also be directly detected, and further mutations in the RNA can be detected.
  • RNA technology needed to amplify by PCR after making it cDNA with reverse transcriptase. Since reverse transcriptase used for reverse transcription generally tends to be mutated, it may cause false detection. Details will be described below, but the present invention is not limited to the following examples.
  • RNA extracted from A549 cells was used as the sample DNA.
  • A549 cells are cultured cells derived from lung cancer tissue, and are known to contain a Gly12Ser mutation. 5 ⁇ g of total RNA extracted from A549 cells was fragmented by sonication (Covaris, s220). The fragmentation processing conditions followed the manufacturer's recommended method. The length of the fragments was evaluated using a bioanalyzer (Agilent). The mode value of the nucleic acid length was 250 bases. The total amount of cleaved RNA was used as the sample RNA.
  • Hybridization 1 ⁇ L of the diluted detection probe solution was mixed with 5 ⁇ L of the sample RNA, and heated at 95 ° C. for 5 minutes using a thermal cycler. After heating, it was left on the desk for 2 minutes until it returned to room temperature. To this solution, 35 ⁇ L of a hybridization solution (composition confirmation: 1 wt% BSA (bovine serum albumin), 5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate), 0.01 wt% salmon sperm DNA solution) In addition, a hybrid solution was obtained. The entire amount was injected into a DNA chip and set in an incubator heated at 32 ° C. Hybridization was performed at 32 ° C.
  • BSA bovine serum albumin
  • SSC sodium dodecyl sulfate
  • the DNA chip was washed with a washing solution (0.5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate)) heated to 30 ° C. for 5 minutes, and then using a spin dryer (Wakken Yakuhin). Dried.
  • a washing solution 0.5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate)
  • a solution in which streptavidin phycoerythrin (Prozyme) was added to a staining solution 50 ng / ⁇ l streptavidin phycoerythrin, 100 mM MES, 1 M NaCl, 0.05 wt% Tween 20, 2 mg / ml BSA (bovine serum albumin) was prepared and dropped on a DNA chip. Incubated at 35 ° C for 5 minutes. The plate was washed with a washing solution (6XSSPE, 0.01 wt% Tween 20) heated to 30 ° C. for 5 minutes and then dried using a spin dryer (Wakken). For the stained DNA chip, a fluorescent signal was detected using a DNA chip scanner (Toray). The scanner was set to 100% laser output and 70% photomultiplier voltage.
  • Table 10 shows the detection results.
  • the wild-type probe since the wild-type probe has the highest signal intensity, it is considered that the T790M mutation does not occur in A549 cells.
  • the signal intensity of the Gly12Ser probe is the highest.
  • A549 cells are known to contain the Gly12Ser mutation, which was consistent with the present detection results.
  • RNA could be detected directly without reverse transcription, and SNP could be detected correctly.
  • Example 5 The invention is described in further detail by another embodiment of human papillomavirus detection.
  • human papillomavirus DNA was detected.
  • both the interpretation that no papillomavirus was present in the human specimen and the interpretation that the nucleic acid extraction or detection work failed Can be considered. It is difficult to distinguish between the two. Such a problem can be solved by using an internal standard.
  • Human papillomavirus DNA cannot be obtained from human specimens not infected with human papillomavirus, but human DNA can be obtained.
  • human DNA can be obtained.
  • a sample in which a plasmid DNA incorporating a papillomavirus base sequence and human genomic DNA is mixed is used in a pseudo manner.
  • the present invention is not limited to the following examples.
  • Table 11 shows capture probes and detection probes for Alu sequences that are repeatedly present in the human genome.
  • the capture probe having the above sequence was synthesized by Operon with a synthetic DNA having an amino group modified at the 5 'end.
  • the detection probe was synthesized by Operon with a biotin label introduced at the 5 'end and 3' end.
  • pHPV16 recombinant plasmid pHPV16 in which genomic DNA of human papillomavirus was cloned was purchased from Human Science Research Resource Bank (Human Science Promotion Foundation) and used. pHPV16 was 16,600 base pairs in length. If the molecular weight of one base pair is 680, 1 ⁇ g is 89 nmol. Human genomic DNA purchased from Clontech was used.
  • the preparation method of sputum sample DNA is shown below. 5 ⁇ g of pHPV16 and human genomic DNA were fragmented by sonication (Covaris, model number: s220). The fragmentation treatment conditions were set to 250 bases according to the manufacturer's recommended method. The length of the fragment was evaluated using a bioanalyzer (Agilent), and the peak top of the fragmented nucleic acid obtained under each treatment condition was 250 bases. The concentration of the cleaved sample DNA was measured using a nanodrop (Thermo Fisher, model number: ND-1000) to determine the concentration of the nucleic acid. From the nucleic acid concentration, the cleaved DNA contained in each cleaved solution was diluted with 1X hybridization solution so that pHPV16 was 1 amol / uL and human genomic DNA was 5 ng / uL.
  • Hybridization 1 ⁇ L of the diluted detection probe solution was mixed with 5 ⁇ L of the sample DNA prepared by mixing the cleaved pHPV16 and human genomic DNA so as to have the composition shown in Table 12, and heated at 95 ° C. for 5 minutes using a thermal cycler. After heating, it was left on the desk for 2 minutes until it returned to room temperature.
  • a 1 ⁇ hybridization solution (1 wt% BSA (bovine serum albumin), 5 ⁇ SSC, 1 wt% SDS (sodium dodecyl sulfate), 50 ng / ml salmon sperm DNA solution, 5 wt% dextran sodium sulfate, 30 % Formamide) was added to give a hybrid solution.
  • the entire amount was injected into a DNA chip and set in an incubator heated at 32 ° C. Hybridization was performed at 32 ° C. for 2 hours while swirling at 250 rpm according to the standard protocol of “3D-Gene”.
  • the DNA chip was washed with a washing solution (0.5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate)) heated to 30 ° C. for 5 minutes, and then a spin dryer (Waken Pharmaceutical Co., Ltd.) was used. And dried. Further, a solution in which streptavidin phycoerythrin (Prozyme) was added to a staining solution (50 ng / ⁇ l streptavidin phycoerythrin, 100 mM MES, 1 M NaCl, 0.05 wt% Tween 20, 2 mg / ml BSA (bovine serum albumin)) was prepared and dropped on a DNA chip.
  • a washing solution 0.5 ⁇ SSC, 0.1 wt% SDS (sodium dodecyl sulfate)
  • a spin dryer Wood Pharmaceutical Co., Ltd.
  • Table 12 shows the wrinkle detection results.
  • sample 1 (5 ng of human genomic DNA), a signal was detected only with the capture probe Probe Alu. Since this sample does not contain pHPV16 DNA, no signal is obtained with the capture probe Probe 16.
  • sample 2 (pHPV16 1 amol, human genomic DNA 5 ng), signals were obtained with the capture probes Probe 16 and Probe Alu. This indicates that pHPV16 and human genomic DNA can be detected simultaneously.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PCT/JP2013/055085 2012-02-27 2013-02-27 核酸の検出方法 WO2013129457A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN201380011166.7A CN104136611B (zh) 2012-02-27 2013-02-27 核酸的检测方法
EP13755881.3A EP2843047B1 (de) 2012-02-27 2013-02-27 Nucleinsäuredetektionsverfahren
CA2865541A CA2865541C (en) 2012-02-27 2013-02-27 Nucleic acid detection method
KR1020147025486A KR102018934B1 (ko) 2012-02-27 2013-02-27 핵산의 검출 방법
JP2013510382A JP6206181B2 (ja) 2012-02-27 2013-02-27 核酸の検出方法
US14/381,366 US20150045249A1 (en) 2012-02-27 2013-02-27 Nucleic acid detection method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012040051 2012-02-27
JP2012-040051 2012-02-27

Publications (1)

Publication Number Publication Date
WO2013129457A1 true WO2013129457A1 (ja) 2013-09-06

Family

ID=49082652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/055085 WO2013129457A1 (ja) 2012-02-27 2013-02-27 核酸の検出方法

Country Status (7)

Country Link
US (1) US20150045249A1 (de)
EP (1) EP2843047B1 (de)
JP (1) JP6206181B2 (de)
KR (1) KR102018934B1 (de)
CN (1) CN104136611B (de)
CA (1) CA2865541C (de)
WO (1) WO2013129457A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015091525A1 (en) * 2013-12-16 2015-06-25 Syddansk Universitet Ras exon 2 skipping for cancer treatment
WO2018008435A1 (ja) * 2016-07-04 2018-01-11 株式会社ダナフォーム 核酸分析方法

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58501703A (ja) * 1981-10-16 1983-10-13 オリオン−イチメ・オイ 微生物鑑別方法及び微生物鑑別試剤の組み合わせ
JPS62229068A (ja) * 1986-03-19 1987-10-07 シタス　コ−ポレイシヨン サンプル中の核酸配列の存在を検出するための液体ハイブリダイゼ−シヨン法及びそのためのキツト
JPH02502250A (ja) * 1987-11-24 1990-07-26 ジェン―プローブ・インコーポレイテッド 核酸ハイブリダイゼーションの増進手段および方法
JPH05501957A (ja) * 1990-06-11 1993-04-15 ビオ　メリウ サンドウィッチハイブリッド化技術によるヌクレオチド配列の検出方法
JPH0775600A (ja) 1993-09-08 1995-03-20 Toyobo Co Ltd 標的核酸の検出法
JPH09507121A (ja) 1993-10-26 1997-07-22 アフィマックス テクノロジーズ ナームロゼ ベノートスハップ 生物学的チップ上の核酸プローブアレー
US5705610A (en) 1990-05-15 1998-01-06 Chiron Corporation Method and apparatus for biopolymer synthesis
JPH10503841A (ja) 1994-06-17 1998-04-07 ザ ボード オブ トランティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体試料から成るミクロ配列を作成するための方法および装置
WO1999047705A1 (en) 1998-03-19 1999-09-23 Novartis Ag Detection method
US6142266A (en) 1997-09-18 2000-11-07 Still Gmbh Energy storing brake for a vehicle
JP2004502464A (ja) * 2000-07-07 2004-01-29 リー，エレン ディップスティック検定における標的核酸の改良型捕捉および検出
US7037659B2 (en) 2002-01-31 2006-05-02 Nimblegen Systems Inc. Apparatus for constructing DNA probes having a prismatic and kaleidoscopic light homogenizer
WO2007034897A1 (ja) * 2005-09-21 2007-03-29 Hiroshima University Ｇテイル配列の長さ測定方法及びそれに用いるキット
JP3922454B2 (ja) 2001-02-08 2007-05-30 日本碍子株式会社 バイオチップ及びその製造方法
JP2007535944A (ja) * 2004-05-04 2007-12-13 ヴェンタナ メディカル システムズ インコーポレイテッド ｉｎｓｉｔｕハイブリダイゼーションのための内部対照
JP4619202B2 (ja) 2005-06-01 2011-01-26 パナソニック株式会社 電気泳動システム

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE121793T1 (de) * 1989-08-11 1995-05-15 Amoco Corp Detektion von pneumocystis carinii durch die verwendung von nukleinsäuresonden.
US5595900A (en) * 1990-02-14 1997-01-21 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5695926A (en) * 1990-06-11 1997-12-09 Bio Merieux Sandwich hybridization assays using very short capture probes noncovalently bound to a hydrophobic support
US5494794A (en) * 1992-10-20 1996-02-27 Emory University Detection of mitochondrial DNA mutations associated with Alzheimer's disease and Parkinson's disease
ATE257861T1 (de) * 1993-09-27 2004-01-15 Arch Dev Corp Methoden und zusammensetzungen zur effizienten nukleinsaeuresequenzierung
JPH0889300A (ja) * 1994-09-28 1996-04-09 Mitsui Toatsu Chem Inc 核酸検出法
GB9507238D0 (en) * 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
CA2255774C (en) * 1996-05-29 2008-03-18 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
WO1999028494A1 (en) * 1997-12-04 1999-06-10 Packard Bioscience Company Methods of using probes for analyzing polynucleotide sequence
AU760236B2 (en) * 1998-06-18 2003-05-08 Exact Sciences Corporation Denaturing gradient affinity electrophoresis and methods of use thereof
JP2002518998A (ja) * 1998-06-24 2002-07-02 セラセンス、インク． ヌクレオチドシーケンスの電気化学的認識用マルチセンサーアレイおよび方法
US6268147B1 (en) * 1998-11-02 2001-07-31 Kenneth Loren Beattie Nucleic acid analysis using sequence-targeted tandem hybridization
EP1313879A2 (de) * 2000-04-10 2003-05-28 Matthew Ashby Methoden zur begutachtung und genetischen analyse von populationen
AU2002230997A1 (en) * 2000-12-15 2002-06-24 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
EP1456409B1 (de) * 2001-11-28 2010-02-24 Bio-Rad Laboratories, Inc. Paralleles scoring von polymorphismen mittels amplifikation und fehlerkorrektur
US7214492B1 (en) * 2002-04-24 2007-05-08 The University Of North Carolina At Greensboro Nucleic acid arrays to monitor water and other ecosystems
DE10228785B4 (de) * 2002-06-23 2007-10-04 Stiftung Alfred-Wegener-Institut für Polar- und Meeresforschung Stiftung des öffentlichen Rechts Detektion von toxischen Algen
AU2002329063A1 (en) * 2002-09-30 2004-04-23 F.Hoffmann-La Roche Ag Oligonucleotides for genotyping thymidylate synthase gene
EP1431398A1 (de) * 2002-12-20 2004-06-23 Evotec OAI AG Verfahren zum Nachweis die Menge eines Analyten in einer Mischung
US20040180369A1 (en) * 2003-01-16 2004-09-16 North Carolina State University Photothermal detection of nucleic acid hybridization
US7354706B2 (en) * 2003-09-09 2008-04-08 The Regents Of The University Of Colorado, A Body Corporate Use of photopolymerization for amplification and detection of a molecular recognition event
EP2163653B1 (de) * 2003-11-10 2013-03-27 Geneohm Sciences, Inc. Nukleinsäurenachweisverfahren mit erhörter Empfindlichkeit
FR2886735B1 (fr) * 2005-06-01 2015-09-11 Biomerieux Sa Procede de marquage ou de traitement d'un echantillon biologique contenant des molecules biologiques d'interet, notamment des acides nucleiques
US8407013B2 (en) * 2005-06-07 2013-03-26 Peter K. Rogan AB initio generation of single copy genomic probes
EP1979490A4 (de) * 2005-11-18 2009-12-23 Childrens Mercy Hospital Abschwächung einer cot-1-dna-verzerrung bei der hybridisierung von nukleinsäure
US8188255B2 (en) * 2006-10-20 2012-05-29 Exiqon A/S Human microRNAs associated with cancer
CN101918590B (zh) * 2007-12-10 2013-03-27 高晓莲 核酸测序
US8932811B2 (en) * 2009-02-27 2015-01-13 Koninklijke Philips N.V. Genomic selection and sequencing using encoded microcarriers
EP2230312A1 (de) * 2009-03-19 2010-09-22 Helmholtz-Zentrum für Infektionsforschung GmbH Sondenverbindung zum Nachweisen und Isolieren von Enzymen sowie Mittel und Verfahren zu ihrer Verwendung
WO2010126913A1 (en) * 2009-04-27 2010-11-04 Gen-Probe Incorporated Methods and kits for use in the selective amplification of target sequences
WO2011027268A2 (en) * 2009-09-01 2011-03-10 Koninklijke Philips Electronics N.V. Devices and methods for microarray selection
JP5901046B2 (ja) * 2010-02-19 2016-04-06 国立大学法人 千葉大学 ＯＡＴＰ１Ｂ３ｍＲＮＡの新規な選択的スプライシングバリアント
CN102329876B (zh) * 2011-10-14 2014-04-02 深圳华大基因科技有限公司 一种测定待检测样本中疾病相关核酸分子的核苷酸序列的方法

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58501703A (ja) * 1981-10-16 1983-10-13 オリオン−イチメ・オイ 微生物鑑別方法及び微生物鑑別試剤の組み合わせ
US4486539A (en) 1981-10-16 1984-12-04 Orioon Corporation Ltd. Detection of microbial nucleic acids by a one-step sandwich hybridization test
JPS62229068A (ja) * 1986-03-19 1987-10-07 シタス　コ−ポレイシヨン サンプル中の核酸配列の存在を検出するための液体ハイブリダイゼ−シヨン法及びそのためのキツト
JPH02502250A (ja) * 1987-11-24 1990-07-26 ジェン―プローブ・インコーポレイテッド 核酸ハイブリダイゼーションの増進手段および方法
US5705610A (en) 1990-05-15 1998-01-06 Chiron Corporation Method and apparatus for biopolymer synthesis
JPH05501957A (ja) * 1990-06-11 1993-04-15 ビオ　メリウ サンドウィッチハイブリッド化技術によるヌクレオチド配列の検出方法
JPH0775600A (ja) 1993-09-08 1995-03-20 Toyobo Co Ltd 標的核酸の検出法
JPH09507121A (ja) 1993-10-26 1997-07-22 アフィマックス テクノロジーズ ナームロゼ ベノートスハップ 生物学的チップ上の核酸プローブアレー
JPH10503841A (ja) 1994-06-17 1998-04-07 ザ ボード オブ トランティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体試料から成るミクロ配列を作成するための方法および装置
US6142266A (en) 1997-09-18 2000-11-07 Still Gmbh Energy storing brake for a vehicle
WO1999047705A1 (en) 1998-03-19 1999-09-23 Novartis Ag Detection method
JP2004502464A (ja) * 2000-07-07 2004-01-29 リー，エレン ディップスティック検定における標的核酸の改良型捕捉および検出
JP3922454B2 (ja) 2001-02-08 2007-05-30 日本碍子株式会社 バイオチップ及びその製造方法
US7037659B2 (en) 2002-01-31 2006-05-02 Nimblegen Systems Inc. Apparatus for constructing DNA probes having a prismatic and kaleidoscopic light homogenizer
JP2007535944A (ja) * 2004-05-04 2007-12-13 ヴェンタナ メディカル システムズ インコーポレイテッド ｉｎｓｉｔｕハイブリダイゼーションのための内部対照
JP4619202B2 (ja) 2005-06-01 2011-01-26 パナソニック株式会社 電気泳動システム
WO2007034897A1 (ja) * 2005-09-21 2007-03-29 Hiroshima University Ｇテイル配列の長さ測定方法及びそれに用いるキット

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Biological Experiment Illustrated - Truly Productive PCR", 1999, SHUJUNSHA CO., LTD., pages: 121 - 125
BLIN ET AL., NUCLEIC ACIDS RES., vol. 3, 1976, pages 2303
FAVALORO, METHODS ENZYMOL., vol. 65, 1980, pages 718
J. CLIN. MICROBIOL., 1995, pages 901 - 905
MYERS; MILLER, CABIOS, vol. 4, 1988, pages 11 - 17
NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 444 - 453
OAEW S. ET AL.: "Sensitivity enhancement in DNA hybridization assay using gold nanoparticle-labeled two reporting probes", BIOSENS. BIOELECTRON., vol. 25, no. 2, 2009, pages 435 - 441, XP026600446 *
SAMBROOK, J. ET AL.: "Molecular Cloning: A Laboratory Manual", 1998, COLD SPRING HARBOR LABORATORY PRESS
SINIKKA PARKKINEN ET AL., JOURNAL OF MEDICAL VIROLOGY, vol. 20, 1986, pages 279 - 288

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015091525A1 (en) * 2013-12-16 2015-06-25 Syddansk Universitet Ras exon 2 skipping for cancer treatment
US10266828B2 (en) 2013-12-16 2019-04-23 Syddansk Universitet RAS exon 2 skipping for cancer treatment
WO2018008435A1 (ja) * 2016-07-04 2018-01-11 株式会社ダナフォーム 核酸分析方法

Also Published As

Publication number Publication date
US20150045249A1 (en) 2015-02-12
KR20140131960A (ko) 2014-11-14
CA2865541C (en) 2019-11-05
EP2843047B1 (de) 2019-10-30
CN104136611B (zh) 2018-03-27
KR102018934B1 (ko) 2019-09-06
EP2843047A1 (de) 2015-03-04
JPWO2013129457A1 (ja) 2015-07-30
CA2865541A1 (en) 2013-09-06
JP6206181B2 (ja) 2017-10-04
EP2843047A4 (de) 2015-11-18
CN104136611A (zh) 2014-11-05

Similar Documents

Publication Publication Date Title
JP6219816B2 (ja) 核酸の増幅方法、および、増幅核酸の検出方法
WO2010021396A1 (ja) Ｄｎａを定量又は検出する方法
EP1818416B1 (de) Verfahren und Kit zum Nachweis von HPV
JP6182300B2 (ja) 標的核酸の検出方法
JP2010017179A (ja) Ｄｎａを定量又は検出する方法
WO2022266513A2 (en) Devices, systems, and methods for analysis of nucleic acids
JP2010017178A (ja) Ｄｎａを定量又は検出する方法
US20160068894A1 (en) RNA Microchip Detection Using Nanoparticle-Assisted Signal Amplification
JP6337470B2 (ja) 核酸の検出方法および核酸検出キット
US9732113B2 (en) Dendrimeric dye-containing oligonucleotide probes and methods of preparation and uses thereof
JP6206181B2 (ja) 核酸の検出方法
JP6248633B2 (ja) 標的核酸の検出方法
JP5613160B2 (ja) ゲノムｄｎａ中の標的配列の検出又は解析方法
JP2014180278A (ja) 核酸の解析方法、そこにおいて使用されるアッセイキット
JP2014187934A (ja) 標的核酸の検出方法
WO2016129609A1 (ja) 標的核酸の検出方法
JP2021040555A (ja) 核酸試料の品質評価方法
WO2016121907A1 (ja) 一本鎖ｄｎａ産物の調製方法
JPWO2015182601A1 (ja) 標的核酸の検出方法
Kamau-Gatogo Development of RNA microchip for pathogen and cancer direct detection
Gül Development of an oligonucleotide based sandwich array platform for the detection of transgenic elements from plant sources using labal-free PCR products

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2013510382

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13755881

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2865541

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14381366

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2013755881

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20147025486

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014021188

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014021188

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140827